Med. praxi. 2025;22(3):192-195 | DOI: 10.36290/med.2025.023

Benzodiazepine addiction

doc. MUDr. Jiří Slíva, Ph.D., MBA
Ústav farmakologie, 3. LF UK, Praha

Benzodiazepines have a number of well-documented pharmacological properties that are widely used in a number of fields of medicine. However, their inappropriate use carries the risk of developing addiction. Treatment often requires a gradual reduction in medication combined with behavioral therapies and support systems that address the psychological aspects of addiction and prevent relapse. The aim of the submitted text is to draw attention to this issue and to point out the relevant context associated with it.

Keywords: benzodiazepines, addiction, disorder, GABA, prevention, withdrawal syndrome, treatment.

Received: March 31, 2025; Revised: April 3, 2025; Accepted: April 4, 2025; Published: June 26, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. Benzodiazepine addiction. Med. praxi. 2025;22(3):192-195. doi: 10.36290/med.2025.023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF

    References

    1. . Ma TT, Wang Z, Qin X, et al. Global trends in the consumption of benzodiazepines and Z­‑drugs in 67 countries and regions from 2008 to 2018: a sales data analysis. Sleep. 2023 Oct 11;46(10):zsad124. doi: 10.1093/sleep/zsad124. PMID: 37094086. Go to original source... Go to PubMed...
    2. . Chomynová P, Grohmanová K, Dvořáková Z, et al. Zpráva o problematickém užívání psychoaktivních léků v České republice 2023. Národní monitorovací středisko pro drogy a závislosti. 2023. Available from: https://www.drogy­‑info.cz/data/obj_files/33914/1242/Zpr%C3%A1va%20o%20problematick%C3%A9m%20u%C5%BE%C3%ADv%C3%A1n%C3%AD%20psychoaktivn%C3%ADch%20 l%C3%A9k%C5%AF%20v%20%C4%8CR%202023_fin.pdf (poslední přístup: 27/03/2025).
    3. . Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma­‑aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol. 1989 Mar;25(3):213-20. Go to original source... Go to PubMed...
    4. . Greenblatt DJ, Arendt RM, Abernethy DR, et al. In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. Br J Anaesth. 1983 Oct;55(10):985-9. Go to original source... Go to PubMed...
    5. . Wafford KA. GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence? Curr Opin Pharmacol. 2005 Feb;5(1):47-52. Go to original source... Go to PubMed...
    6. . Basińska­‑Szafrańska A. Delayed crises following benzodiazepine withdrawal: deficient adaptive mechanisms or simple pharmacokinetics? Detoxification assisted by serum­‑benzodiazepine elimination tracking. Eur J Clin Pharmacol. 2022 Jan;78(1):101-110. Go to original source... Go to PubMed...
    7. . Pétursson H. The benzodiazepine withdrawal syndrome. Addiction. 1994 Nov;89(11):1455-9. Go to original source... Go to PubMed...
    8. . Fialip J, Aumaitre O, Eschalier, A et al. Benzodiazepine withdrawal seizures: analysis of 48 case reports. Clin Neuropharmacol. 1987 Dec;10(6):538-44. Go to original source...
    9. . Riegel AC, Kalivas PW. Neuroscience: Lack of inhibition leads to abuse. Nature. 2010 Feb 11;463(7282):743-4. Go to original source... Go to PubMed...
    10. . Roy­‑Byrne PP, Hommer D. Benzodiazepine withdrawal: overview and implications for the treatment of anxiety. Am J Med. 1988 Jun;84(6):1041-52. Go to original source... Go to PubMed...
    11. . de Gier NA, Gorgels WJ, Lucassen PL, et al. Discontinuation of long­‑term benzodiazepine use: 10-year follow­‑up. Fam Pract. 2011 Jun;28(3):253-9. Go to original source... Go to PubMed...
    12. . Darker CD, Sweeney BP, Barry JM, et al. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev. 2015;2015(5):CD009652. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.